Free Trial
NASDAQ:SYRE

Spyre Therapeutics Q3 2023 Earnings Report

Spyre Therapeutics logo
$12.68 +0.18 (+1.40%)
As of 02:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Spyre Therapeutics EPS Results

Actual EPS
-$3.43
Consensus EPS
-$0.44
Beat/Miss
Missed by -$2.99
One Year Ago EPS
N/A

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
3:00AM ET

Upcoming Earnings

Spyre Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Earnings Documents

Spyre Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE), a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

View Spyre Therapeutics Profile

More Earnings Resources from MarketBeat